Search through
Vildagliptin is an orally active pharmaceutical ingredient used as a DPP-4 inhibitor for the management of type 2 diabetes mellitus. Vildagliptin or VILDAGLIPTIN [EMA EPAR] functions by increasing incretin levels, which regulate glucose homeostasis through enhanced insulin secretion and suppressed glucagon release. Vildagliptin has suitability for formulation development, clinical research, and pilot-scale API production. Also referred to as (LAF237, Vildagliptin Hydrochloride) by Vildagliptin manufacturers, characterised by high potency, oral bioavailability, and metabolic stability. We are the trusted Vildagliptin supplier worldwide, ensuring reliable lead times and consistent quality for pharmaceutical manufacturing and research.
Vildagliptin is an orally active pharmaceutical ingredient used as a DPP-4 inhibitor for the management of type 2 diabetes mellitus. Vildagliptin or VILDAGLIPTIN [EMA EPAR] functions by increasing incretin levels, which regulate glucose homeostasis through enhanced insulin secretion and suppressed glucagon release. Vildagliptin has suitability for formulation development, clinical research, and pilot-scale API production. Also referred to as (LAF237, Vildagliptin Hydrochloride) by Vildagliptin manufacturers, characterised by high potency, oral bioavailability, and metabolic stability. We are the trusted Vildagliptin supplier worldwide, ensuring reliable lead times and consistent quality for...
Chemical Properties & Specifications
H413 (90.1%): May cause long lasting harmful effects to aquatic life [Hazardous to the aquatic environment, long-term hazard]
P273, and P501
Treatment of type 2 diabetes mellitus.
DPP-4 inhibition increases incretin levels, enhancing insulin secretion.
High oral absorption allows flexible dosing.
Resistant to rapid metabolism, enabling consistent therapeutic effects.
Preferred in preclinical and clinical research on DPP-4 inhibitors and glucose metabolism studies.
Store at 15–25°C (59–77°F)
Protect from moisture and light; keep in tightly sealed containers
Used as an oral DPP-4 inhibitor in type 2 diabetes management.
Inhibits DPP-4 enzyme, increasing incretin levels and improving glucose regulation.
Typically ≥99% by HPLC assay.
Pharmaceutical manufacturers, contract development organizations, and clinical research labs.
Handle in a controlled environment with gloves and protective eyewear.
Used in oral tablets and combination therapies with other anti-diabetic agents.
Yes, it is suitable for both preclinical and clinical research.
